BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. Calling the study results “promising,” the company noted that those results will provide vital supporting evidence when Aditxt moves forward with an investigational new drug (“IND”) application with the regulatory agencies. According to the announcement, ADI-100 is made of two DNA molecules that together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds. The process of modulating the immune system by restoring/inducing tolerance is a unique mechanism of action, the company noted, and has potential to offer huge efficacy and safety benefits because no immunosuppression is involved. “Our drug is truly antigen-specific in the treatment of autoimmune diseases,” said Aditxt senior vice president of clinical development-autoimmunity Joachim-Friedrich Kapp, MD, PhD, in the press release. “In preparation of the clinical study, we performed a toxicology study and found no premature death; no signs of local intolerance; no test item-related influence on clinical signs, body weight and body weight gains, food consumption, biochemistry or urinalysis. No antinuclear antibodies, no macroscopic postmortem findings, no changes in histopathology were noted, confirming the safety profile of our drug product, which we have seen in all preclinical experiments before. . . . In addition, and separately, we clearly demonstrated that our drug does not display any general immunosuppressive effect. This was shown in safety studies, when using a listeria model for infection and a melanoma model for potential effects on tumor growth. As one could have predicted, considering the mechanism of action, there was no interference with the immune system and its capacity to fight infection or tumor disease, at all. These findings are very promising and certainly will support our story when filing the IND.”

To view the full press release, visit https://ibn.fm/TvSNW

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The company’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork